Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/35793
Title: Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Authors: 
Keywords: 
Issue Date: Nov-2018
Citation: Cancer Med.2018 Nov;(7)11:5382-5393
Abstract: The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.
PMID: 30123970
URI: https://hdl.handle.net/20.500.12530/35793
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC6246927.pdf355.16 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.